Post-earnings recap
Reported
Tue, Aug 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 6.04%. The lack of revenue data leaves some uncertainty, but management's focus on ongoing projects suggests they are working towards future growth. Investors may view the EPS beat as a sign of operational progress.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | +9.20% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their current projects. They did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing projects and research advancements as key focus areas.